Dyadic International, Inc. DYAI
0.36 USD -0.02 (-4.26%)
At closeNov 3, 2026, 4:00 PM EST
0.39 +0.03 +8.94%
After hours · Nov 3, 4:00 PM ET
0.36 Day range 0.3728
0.34 52-week range 1.60
- YTD
- -61.70%
- 1 year
- -66.67%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Dyadic International (NASDAQ:DYAI) stock rose 13.4% to $0.43 during Tuesday's pre-market session. The market value of their outstanding shares is at $15.0 million. Aethlon Medical…
globenewswire.com Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026 JUPITER, Fla., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology…
defenseworld.net Financial Survey: Lisata Therapeutics (NASDAQ:LSTA) vs. Dyadic International (NASDAQ:DYAI) Dyadic International (NASDAQ: DYAI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
defenseworld.net Dyadic International Targets Commercial Traction as Life Sciences Products Launch Dyadic International (NASDAQ: DYAI) is moving from technology-platform development toward commercial execution, with multiple products entering the market through its own channels and partnerships,…
defenseworld.net Dyadic International (NASDAQ:DYAI) & Amylyx Pharmaceuticals (NASDAQ:AMLX) Critical Review Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) and Dyadic International (NASDAQ: DYAI - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the…
defenseworld.net Dyadic International (NASDAQ:DYAI) Stock Breaks Below 50-Day Moving Average – Here’s Why Dyadic International Inc. (NASDAQ: DYAI - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.72 and traded…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics…
seekingalpha.com Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 Transcript
defenseworld.net Dyadic International (NASDAQ:DYAI) Stock Passes Below 50-Day Moving Average – Time to Sell? Dyadic International Inc. (NASDAQ: DYAI - Get Free Report) passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $0.88 and traded as low as…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)…
benzinga.com Dyadic International Announces Definitive Agreements For $2.9M Registered Direct Offering And Concurrent Private Placement Of Warrants With Institutional Investor Dyadic International, Inc. (NASDAQ:DYAI) (the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food and…
globenewswire.com Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein…
seekingalpha.com Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
benzinga.com Dyadic International Q2 EPS $(0.06) Misses $(0.04) Estimate, Sales $961.138K Miss $993.333K Estimate Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 50 percent. This is unchanged from the same period last…
globenewswire.com Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology…
defenseworld.net Reviewing Dyadic International (NASDAQ:DYAI) and Myriad Genetics (NASDAQ:MYGN) Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast…
benzinga.com Dyadic International Inks New Development, Commercial License Agreement With European Biotechnology Firm For Additional Precision Fermented Dairy Proteins Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences,…
globenewswire.com Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing…
globenewswire.com Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026 JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology…
globenewswire.com Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days JUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, today announced that, within approximately…- benzinga.com Dyadic International Regains Nasdaq Compliance Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food
globenewswire.com Dyadic Announces Continued Listing on the Nasdaq Capital Market JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's regular session. The company's market cap stands at $36.8 million. Wellgistics Health (NASDAQ:WGRX) shares…
globenewswire.com Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing…
globenewswire.com Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dyadic's Ebola preparedness work highlights C1's potentia- benzinga.com Dyadic Announces Japan Patent Office Allowance Of Claims Covering Its Proprietary Thermothelomyces Heterothallica Recombinant Protein Expression Technology The Japan Patent Office allowed claims covering novel aspects of Dyadic’s proprietary Thermothelomyces heterothallica recombinant protein expression technology. This milestone adds significant…
globenewswire.com Dyadic Expands IP Protection and Business Development Activities in Japan JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the…
newsfilecorp.com An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic…
benzinga.com Dyadic Highlights Increasing Interest In Proprietary C1 Protein Production Platform As Global Infectious Disease Preparedness Efforts Intensify In Response To Ongoing Bundibugyo Ebola Virus Outbreak Dyadic International, Inc. (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions ("Dyadic" or the "Company"), a biotechnology company focused on the development and commercialization of scalable microbial…
globenewswire.com Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on the…
benzinga.com U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/- benzinga.com Dyadic's Applied Biosolutions Unit Collaborates With Scripps Research To Evaluate Monoclonal Antibody And Vaccine Candidates Targeting Hantaviruses, Including Andes Virus A series of recently reported hantavirus and Ebola cases worldwide have underscored the importance of pandemic preparedness and highlighted the need to improve the speed, scalability, flexibility,…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Transcript: Dyadic International Q1 2026 Earnings Conference Call 
benzinga.com Dyadic International Q1 EPS $(0.05) Misses $(0.04) Estimate, Sales $1.111M Beat $900.000K Estimate Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses of…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Dyadic International Gets Nasdaq Warning Over Listing Rules, Faces Delisting Risk On March 27, 2026, Dyadic International, Inc. (the "Company" or "Dyadic") received a deficiency notice (the "Notice") from the Nasdaq Listing Qualifications staff (the "Staff") of The Nasdaq Stock…
- benzinga.com Dyadic International Q4 EPS $(0.06) Misses $(0.04) Estimate, Sales $565.526K Miss $1.343M Estimate Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 33.33 percent. This is a 20 percent decrease over losses of…
- benzinga.com Earnings Scheduled For March 25, 2026
benzinga.com Dyadic Applied BioSolutions Enters Into Original Equipment Manufacturer Distribution Agreement With Integrated Biotherapeutics To Expand Protein Product Reach Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life…- benzinga.com Dyadic Applied BioSolutions And Inzymes Announced Planned 2026 Commercialization Of Recombinant Non-animal Bovine Chymosin, Key Enzyme Used In Cheese Production And Dairy Processing Completion of these development activities represents a contractual milestone under the parties' 2023 development and commercialization agreement focused on non-animal dairy enzymes produced using…
- benzinga.com Dyadic Applied Biosolutions Announces Commercial Launch Of AlbuFree DX, rHA Product Produced Using Dyadic's Proprietary Filamentous Fungal Expression Technology Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life…
benzinga.com Dyadic Applied BioSolutions Expands Collaboration With Fermbox Bio To Manufacture And Commercialize Animal-Free Proteins And Enzymes Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for life…- benzinga.com Dyadic Applied Biosolutions Announced A Commercial Agreement With Opes Diagnostics To Support The Commercial Launch Of Dyadic's Recombinant Human Transferrin, Bovine Transferrin, Human FGF, And Bovine FGF Products For Use In Serum-free Cell Culture Media Applications Under the agreement, Opes will leverage its existing commercial relationships and market experience to identify and engage potential customers primarily in Europe, Israel, and Asia to accelerate…
- benzinga.com Market-Moving News for December 1st QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfront Payment; Co. Eligible To receive Up To $592M In Milestones As Well As Royalties DYAI: 35% |…
- benzinga.com Dyadic Applied BioSolutions And BRIG BIO Signs Development And Commercialization Agreement To Jointly Develop And Commercialize Recombinant Bovine Alpha-Lactalbumin Dyadic Applied BioSolutions ("Dyadic"), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial…
- benzinga.com Dyadic International Q3 EPS $(0.06) Misses $(0.04) Estimate, Sales $1.165M Beat $1.100M Estimate Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 39.53 percent. This is a 500 percent decrease over losses…
- benzinga.com Earnings Scheduled For November 12, 2025